Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews Molecular Cell Biology
Dasatinib is an Orally Active Dual Bcr-Abl and Src Family Tyrosine Kinase Inhibitor | MedChemExpress
The tyrosine kinase c-Abl potentiates interferon-mediated antiviral immunity by STAT1 phosphorylation - ScienceDirect
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade | Cell Communication and Signaling | Full Text
Hematology Reports | Free Full-Text | Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
Response and Resistance to BCR-ABL1-Targeted Therapies
Frontiers | The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
JCI - Applying the discovery of the Philadelphia chromosome
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer - Oliver Hantschel, 2012
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface* - Journal of Biological Chemistry
Mechanism of Action of BCR-ABL and of Its Inhibition by Imatinib. Panel... | Download Scientific Diagram
Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... | Download Scientific Diagram
shRNA Loss-of-Function Screen Identifies Alternate Pathway for BCR-ABL - Cellecta
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Figure 1 from STI571: targeting BCR-ABL as therapy for CML. | Semantic Scholar
A model for the regulation of BCR-ABL nuclear import through conformational interplay between the kinase domain, the FABD and the NLS region.
Frontiers | Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia
Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia | NEJM
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade | Cell Communication and Signaling | Full Text
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. - Australian Medical Student Journal
BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion protein - YouTube
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics: Cancer Cell
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL | IntechOpen
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance | Haematologica
![PDF] Molecular Pathways Molecular Pathways : BCR-ABL | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7afde5a58c37047c83cde7051c4024ff35912884/2-Figure1-1.png "PDF] Molecular Pathways Molecular Pathways : BCR-ABL | Semantic Scholar")